Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07621718 |
| Title | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) (RASolute 305) |
| Acronym | RASolute 305 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Revolution Medicines, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Moffitt Cancer Center | RECRUITING | Tampa | Florida | 33612 | United States | Details |
| Piedmont Healthcare | RECRUITING | Atlanta | Georgia | 30318 | United States | Details |
| Johns Hopkins University | RECRUITING | Baltimore | Maryland | 21287 | United States | Details |